Imatinib pharmacokinetics and its correlation with response in chronic-phase chronic myelogenous leukemia
Not Applicable
- Conditions
- chronic myelogenous leukemia in chronic-phase
- Registration Number
- JPRN-UMIN000001125
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Previous history of anti-leukemic therapy other than imatinib (except hydroxycarbamide at initial phase or steroids for non-anti-leukemia purposes) Pts taking drugs with known pahrmacokinetic interaction with imatinib Cr equal to or greater than 1.6mg/dl, AST/ALT equal to or greater than 2 times of NUL Positive serologic tests for syphilis, HBV or HCV
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method molecular response
- Secondary Outcome Measures
Name Time Method cytogenetic response